Ocugen (OCGN) Operating Leases (2019 - 2026)
Ocugen's (OCGN) quarterly Operating Leases came in at $4.1 million in Q1 2026, up 20.01% YoY from $3.4 million in Q1 2025, and up 17.4% on a QoQ basis from $3.5 million in Q4 2025.
Ocugen (OCGN) Operating Leases (2019 - 2026) Analysis & Trends
Ocugen (OCGN) has 8 years of Operating Leases data on file, last reported at $4.1 million in Q1 2026.
- Quarterly Operating Leases rose 20.01% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (up 20.01% YoY) and the FY2025 annual result came in at $3.5 million, down 8.82% from the prior year.
- Operating Leases advanced to $4.1 million in Q1 2026, from $3.5 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $4.8 million in Q2 2025 to a low of $1.2 million in Q1 2022.
- A 5-year average of $3.6 million and a median of $3.8 million in 2022 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases surged 231.84% — and 2023, when it declined 15.94%.
- Tracing OCGN's Operating Leases over 5 years: stood at $4.1 million in 2022, then decreased by 12.68% to $3.6 million in 2023, then rose by 7.43% to $3.8 million in 2024, then slipped by 8.82% to $3.5 million in 2025, then increased by 17.4% to $4.1 million in 2026.
- The last three Operating Leases figures came in at $4.1 million (Q1 2026), $3.5 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.88 Mn |
| Mar 31, 2026 | 4.10 Mn |
| Dec 31, 2025 | 3.49 Mn |
| Sep 30, 2025 | 3.71 Mn |
| Jun 30, 2025 | 4.80 Mn |
| Mar 31, 2025 | 3.42 Mn |
| Dec 31, 2024 | 3.83 Mn |
| Sep 30, 2024 | 3.90 Mn |
| Jun 30, 2024 | 4.01 Mn |
| Mar 31, 2024 | 4.00 Mn |
| Dec 31, 2023 | 3.57 Mn |
| Sep 30, 2023 | 3.16 Mn |
| Jun 30, 2023 | 3.31 Mn |
| Mar 31, 2023 | 3.45 Mn |
| Dec 31, 2022 | 4.09 Mn |
| Sep 30, 2022 | 3.76 Mn |
| Jun 30, 2022 | 3.89 Mn |
| Mar 31, 2022 | 1.18 Mn |
| Dec 31, 2021 | 1.23 Mn |
| Sep 30, 2021 | 1.28 Mn |